BidaskClub upgraded shares of Celgene (NASDAQ:CELG) from a strong sell rating to a sell rating in a report published on Wednesday.

A number of other research analysts have also weighed in on CELG. Zacks Investment Research lowered shares of Celgene from a buy rating to a hold rating in a research note on Wednesday, September 26th. Cantor Fitzgerald started coverage on shares of Celgene in a research note on Monday, October 1st. They issued an overweight rating and a $100.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Celgene in a research note on Thursday, October 11th. Leerink Swann set a $112.00 price target on shares of Celgene and gave the company a hold rating in a research note on Friday, October 26th. Finally, UBS Group set a $94.00 price target on shares of Celgene and gave the company a buy rating in a research note on Saturday, October 27th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $116.99.

Shares of Celgene stock opened at $70.08 on Wednesday. The stock has a market capitalization of $50.91 billion, a P/E ratio of 10.25, a P/E/G ratio of 0.45 and a beta of 1.50. Celgene has a twelve month low of $66.62 and a twelve month high of $110.81. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.02 by $0.27. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%. Sell-side analysts forecast that Celgene will post 7.45 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ayalon Holdings Ltd. purchased a new position in Celgene in the 2nd quarter worth approximately $100,000. Atlantic Trust LLC purchased a new stake in shares of Celgene during the 2nd quarter valued at approximately $101,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Celgene during the 3rd quarter valued at approximately $132,000. City Holding Co. purchased a new stake in shares of Celgene during the 2nd quarter valued at approximately $143,000. Finally, Sun Life Financial INC raised its position in shares of Celgene by 528.9% during the 2nd quarter. Sun Life Financial INC now owns 1,918 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 1,613 shares during the period. 72.87% of the stock is currently owned by institutional investors and hedge funds.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: How to invest in a bear market

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.